Think­ing big, Bay­er’s Ax­el Bou­chon tack­les stem cell field with $225M start­up part­nered with Ver­sant

Bay­er’s Ax­el Bou­chon has struck again.

Less than four months since the Bay­er ex­ec struck a deal with CRISPR Ther­a­peu­tics to launch a gene edit­ing JV named Case­bia, he’s back with a new col­lab­o­ra­tion, this time fo­cused on stem cells.

This time Bay­er and Bou­chon are team­ing up with Ver­sant Ven­tures to fi­nance a new com­pa­ny called Blue­Rock, hand­ing over $225 mil­lion in fi­nanc­ing to pur­sue new re­gen­er­a­tive med­i­cines for heart dis­ease and Parkin­son’s, ac­cord­ing to the Wall Street Jour­nal, which was hand­ed the ex­clu­sive ahead of a for­mal an­nounce­ment ear­ly next week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER